<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Ped Hematol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Ped Hematol Oncol</journal-id><journal-id journal-id-type="publisher-id">IJPHO</journal-id><journal-title-group><journal-title>Iranian Journal of Pediatric Hematology and Oncology</journal-title></journal-title-group><issn pub-type="ppub">2008-8892</issn><issn pub-type="epub">2228-6993</issn><publisher><publisher-name>Shahid Sadoughi University of Medical Sciences</publisher-name><publisher-loc>Yazd, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25598955</article-id><article-id pub-id-type="pmc">4293514</article-id><article-id pub-id-type="publisher-id">ijpho-4-151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Efficacy of Recombinant Human Erythropoietin in Treatment Chemotherapy Induced Anemia in Children Diagnosed with a Solid Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hiradfar</surname><given-names>AA</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Banihosseinian</surname><given-names>M</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Pediatric Hematology and Oncology, Tabriz of University of Medical Sciences, Iran </aff><aff id="aff2"><label>2</label>Children Cure and Health Hospital, Tabriz of University of Medical Sciences, Iran</aff><aff id="aff3"><label>3</label>Pediatric Health Research Center, Tabriz University of Medical Sciences, Iran </aff><aff id="aff4"><label>4</label>Children Cancer Clinic, Children Cure and Health Hospital, Tabriz of University of Medical Sciences, Iran</aff><author-notes><corresp id="cor1">Corresponding Author: Hiradfar A MD, Sheshgalan Ave, Department of Pediatrics, Tabriz Children Hospital, Tabriz, Iran. Email: hiradfarataolah@yahoo.com.</corresp></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2014</year></pub-date><volume>4</volume><issue>4</issue><fpage>151</fpage><lpage>159</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2014</year></date></history><permissions><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Recombinant human erythropoietin (rHuEPO) treatment can increase hemoglobin levels and decrease transfusion requirements. This study aims to investigate how blood transfusion influences Hemoglobin levels in patients receiving rHuEPO for 12 weeks.</p></sec><sec><title>Materials and Methods</title><p>This was a case-control study of 60 patients less than 15 years with anemia and a solid tumor in any location between February 2013 and March 2014. Median age of the patients were 6.27&#x000b1;0.58 years (range, 0.9-14 years). The patients were randomly assigned in two groups of rHuEPO receiving group and control group. 29 Patients in rHuEPO group received 150 IU/kg/dose rHuEPO subcutaneously, 3 times a week, for 12 weeks. The number of patients received transfusion during the treatment period was compared in the preceding 12 weeks. Also, adverse events (AE) were recorded at the 4<sup>th</sup>, 8<sup>th</sup>, and 12<sup>th</sup> weeks. </p></sec><sec><title>Results</title><p>Mean hemoglobin levels, before and after study, in rHuEPO group were 8.85&#x000b1;1.01 g/dl and 9.90&#x000b1;0.29 g/dl, respectively (p&#x0003c;0.001) and in control group were, 9.00&#x000b1;0.09 g/dl and 7.81&#x000b1;0.23 g/dl, respectively (p=0.25). Among 60 patients initially eligible the present study, 57 (29 in rHuEPO group and 28 in control group) completed study course.There was a significant decrease in transfusion requirements in the rHuEPO receiving group (p=0.004). 5 (17.2%) patients in the rHuEPO group needed a blood transfusion, whereas 15 (53.6%) patients needed a transfusion in the control group. rHuEPO occasioned hypertension in one patient at 4<sup>th</sup> week that caused to end the treatment. All other AE were transient, which did not reoccur after the transient discontinuation of the medication (p&#x0003c;0.05).</p></sec><sec><title>Conclusions</title><p>Results showed that the rHuEPO (150 IU/kg/day, 3 times a week) was effective in increasing hemoglobin levels as well as decreasing blood transfusion requirements in children with anemia following intensive chemotherapy.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Anemia</kwd><kwd>Recombinant Human Erythropoietin</kwd><kwd>Chemotherapy</kwd><kwd>Solid cancer</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Severe anemia requiring Red Blood Cell (RBC) transfusion is a frequent complaint of chemotherapy [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>]. In children with cancer, anemia has many causes including: chemotherapy-induced bone marrow suppression, hemolysis, blood loss, and erythropoietin deficiency induced by nephrotoxicity of chemotherapy medication [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B7" ref-type="bibr">7</xref>]. It is well-known that blood transfusion is associated with numerous adverse effects such as the transmission of infectious diseases (HIV, HBV, HCV, and CMV), hemolysis, and Graft-Versus-Host Disease (GVHD). </p><p>Recombinant Human Erythropoietin (rHuEPO) has been used to reduce the need for RBC transfusion in the treatment of chemotherapy-induced anemia [<xref rid="B8" ref-type="bibr">8</xref>-<xref rid="B13" ref-type="bibr">13</xref>]. Some researchers believe that chemotherapy regimens containing cisplatin (CDDP) are more associated with chemotherapy-induced anemia through drug-induced nephrotoxicity [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B16" ref-type="bibr">16</xref>]. On the other hand, other researchers believe that endogenous erythropoietin level does not significantly reduce anemia in these children, rather bone marrow response to erythropoietin is relatively reduced [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B15" ref-type="bibr">15</xref>]. </p><p>Maintaining a higher hemoglobin concentration during chemotherapy results in a better quality of life (QOL) and may affect survival [<xref rid="B19" ref-type="bibr">19</xref>-<xref rid="B22" ref-type="bibr">22</xref>]. RHuEPO treatment has been shown to improve QOL in patients with chemotherapy regardless of cancer type and the response to chemotherapy along with reducing the need for transfusions [<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B22" ref-type="bibr">22</xref>]. Currently, many studies support health benefits of rHuEPO in the treatment of chemotherapy-induced anemia in adult populations [<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B23" ref-type="bibr">23</xref>-<xref rid="B25" ref-type="bibr">25</xref>]. Few clinical trials have been conducted on children which can recommend a standard dosage and adequate course of treatment for rHuEPO in this age group [<xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B26" ref-type="bibr">26</xref>-<xref rid="B30" ref-type="bibr">30</xref>]. Dosage and duration of treatment with recombinant human erythropoietin were different in various studies. In most clinical trials, rHuEPO has been used in the treatment of anemia in cancer children with dosage of 150 to 900 units/ kg/ dose, 3 days per week to once a week, for a course up to 12 weeks.</p><p>This study was conducted to show positive effects of rHuEPO in the treatment of chemotherapy-induced anemia in children, and reducing the need for RBC transfusion. </p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><p>
<bold>Patients </bold>
</p><p>This was a case-control study. 98 pediatric patients diagnosed with a solid tumor were treated between February 2013 and march 2014 at the Oncology Department of Tabriz children hospital in Iran. Among 98 patients with solid tumor, 60 patients who fulfilled inclusion criteria were eligible to our study. The selected patients randomly assigned into control and rHuEPO receiving groups. According to malignancy type, different chemotherapy medications were used to treat the participants including: cisplatin, vincristine, cyclophosphamide, Ifosphamide, dactinomycin, procarbazine, etoposide, vinbalstine, adriamycin, cytarabine, methotrexate, bleomycin, and lomustine. In patients with Wilm&#x02019;s tumor, Rhabdomyosarcoma, and Ewing sarcoma radiotherapy was used along with chemotherapy. On weekly basis, all participating patients underwent physical examination and blood pressure control, as well as complete blood count (CBC) test. In the course of study, renal function was evaluated in patients undergoing chemotherapy containing CDDP. </p><p>Anemia was defined as hemoglobin less than 10 g/dl for participating patients based on American Association of Clinical Oncology (ASCO) guidelines for cancer patients with chemotherapy-induced anemia [<xref rid="B31" ref-type="bibr">31</xref>]. </p><p>Including criteria: Patients aged &#x0003c;15 years diagnosed with cyto-histological solid tumor in any location as well as anemia associated to chemotherapy. There was no initial bone marrow metastasis in any of the participating patients. Patients never treated with rHuEPO before. Participants had normal renal, liver, and lung functions. All hematologic parameters including: reticulocyte count, serum ferritin level and serum folate level, Serum vitamin B12, direct and indirect Coomb&#x02019;s test, as well as arterial blood gases were normal. The Patients had no blood transfusion history over the last month.</p><p>Patients were excluded if have a active hemorrhage, Hemolysis, liver dysfunction, renal failure, or pulmonary dysfunction during study or any serious side effects of rHuEPO such as uncontrolled hypertension, deep vein thrombosis, and polycythemia in participating patients.</p><p>
<bold>Treatment protocol</bold>
</p><p>rHuEPO was given at a 150 IU/kg/dose, 3 times a week, subcutaneously (rHuEPO made by Cilag Inc (Zug, Switzerland) and marketed as EPREX) in 60 patients. If a patient had any complaints in the process of rHuEPO treatment or any of exclusion criteria, drug administration was stopped. Patients with Hb levels less than 7 g/dl were given blood transfusions based on local guidelines at Oncology Department of Tabriz Children Hospital, Iran. </p><p>Granulocyte Colony-Stimulating Factor (G-CSF) with dose of 5&#x000b5;g/kg, subcutaneously, was used routinely for the significant neutropenic (defined as a neutrophil count &#x0003c; 1000/mm<sup>3</sup>) patients in both groups according to local guidelines at Oncology Department of Tabriz Children Hospital, Iran. The use of G-CSF was stopped when the neutrophil count reached to 10,000/mm<sup>3</sup>. At the end of the 12 weeks, the need for blood transfusion and Hb levels were compared in both groups.</p><p>
<bold>Ethical Considerations</bold>
</p><p>The written informed consent was obtained from parent or guardian of each patient who was signed in the presence of clinical investigator and a witness in the participating institution. The research protocol was approved by the Ethics committee of Pediatric Health Research Center, Tabriz University of Medical Sciences. Helsinki Declaration criteria for Ethical Guidelines for Medical Research involving Human Subjects were followed [<xref rid="B32" ref-type="bibr">32</xref>].</p><p>
<bold>Data collection</bold>
</p><p>All data obtained from patients were completed by the clinical investigator in the participating institution. The patient's clinical evolution, rHuEPO dose, and lab test results were (hemoglobin, white blood count as well as platelet count at treatment onset and termination) recorded weekly during. </p><p>The last Hb level before transfusion of patients, who had transfusions during the study, was recorded and included as a final Hb level for databases analysis in both groups. Adverse events were recorded carefully for each participating patients by the clinical investigator during the study. Data analysis was performed on data from patients completing treatment.</p><p>Efficacy was measured against the study hypothesis and need for RBC transfusions during the study through comparing <strike>to</strike> the number of transfusions in the 12 weeks. Hemoglobin response during rHuEPO treatment was evaluated by calculating the difference between initial and final Hb levels. </p><p>
<bold>Statistical analysis</bold></p><p>Databases were created in Excel spreadsheets and processed using SPSS version 18 statistical software program and P&#x02013;values less than 0.05 were considered significant. Chi-Square test was used to compare transfusion requirements between two groups. Mann-Whitney test was used to compare Hb levels in patients treated with or without CDDP and G-CSF. We used The Wilcoxon test to determine the significance of Hb increments. </p></sec><sec sec-type="results"><title>Results</title><p>Among 60 patients initially eligible the present study, 57 (29 in rHuEPO group and 28 in control group) completed study course and were included in the data analysis. Patients&#x02019; malignancy types are presented in <xref ref-type="table" rid="T1">Table I</xref>. </p><p>Three patients were withdrawn by clinical investigator because of adverse effects; one was withdrawn due to uncontrolled high blood pressure at week 4 in rHuEPO group; the second one due to renal failure at week 6 in control group; and the last one due to hemolysis at week 3 in control group. </p><p>There were 30 boys and 27 girls with median age 6.27&#x000b1;0.58 years (range, 0.9-14 years) (<xref ref-type="table" rid="T2">Table II</xref>). Initial mean platelets count in rHuEPO group and control group were 245,000&#x000b1;82,000/mm3 and 207,000&#x000b1;63,000/mm3, respectively (p=0.6). Initial mean absolute neutrophil count (ANC) in rHuEPO group and control group were 4350&#x000b1;1200/mm3 and 3860&#x000b1;1050/mm3, respectivelt (p=0.8). </p><p>The mean Hb levels, before and after study, in rHuEPO group were 8.85&#x000b1;1.01 g/dl and 9.90&#x000b1;0.29 g/dl, respectively (P=&#x0003c;0.001). Mean Hb levels, before and after study, in control group were 9.00&#x000b1;0.09 g/dl and 7.81&#x000b1;0.23 g/dl, respectively (P=0.25). In the rHuEPO group, the increase in hemoglobin, began from the 5<sup>th</sup> to 6<sup>th</sup> week, and continued to the end with an ascending trend. The mean hemoglobin level was 8.90&#x000b1;0.10 g/dl, 8.99&#x000b1;0.14 g/dl, 9.23&#x000b1;0.24 g/dl, 9.57&#x000b1;0.27 g/dl, and 9.68&#x000b1;0.28 g/dl, and 9.90&#x000b1;0.29 g/dl respectively in the rHuEPO group in the 2<sup>nd</sup>, 4<sup>th</sup>, 6<sup>th</sup>, 8<sup>th</sup>, 10<sup>th</sup>, and 12<sup>th</sup> weeks of treatment. While, it was 8.70&#x000b1;0.58 g/dl, 8.30&#x000b1;0.82 g/dl, 8.03&#x000b1;0.92 g/dl, 7.74&#x000b1;1.02 g/dl, and 7.60&#x000b1;1.03 g/dl, and 7.80&#x000b1;1.23 g/dl respectively in the control group (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><p>Among the participants, 25 patients were treated with a chemotherapy protocol containing cisplatin, of whom, 11 were in rHuEPO group. At the end of the study, the difference in hemoglobin level was insignificant in patients receiving cisplatin (P=0.36). The mean initial hemoglobin levels in the rHuEPO group with or without receiving cisplatin were 8.89&#x000b1;0.21 g/dl and 8.83&#x000b1;0.11 g/dl, respectively. At the end of the study, hemoglobin levels increased to 9.67&#x000b1;0.49 g/dl and 10.03&#x000b1;0.38 g/dl, respectively in the rHuEPO group, with and without receiving cisplatin in their chemotherapy protocol (<xref ref-type="table" rid="T3">Table III</xref>). The mean initial hemoglobin levels in the rHuEPO group with or without receiving cisplatin were 8.89&#x000b1;0.21 g/dl and 8.83&#x000b1;0.11 g/dl, respectively (p=0.35). At the end of the study, hemoglobin levels increased to 9.67&#x000b1;0.49 g/dl and 10.03&#x000b1;0.38 g/dl, respectively in the rHuEPO group, with and without receiving cisplatin in their chemotherapy protocol (p=0.51). During the study, 5 patients (17.2%) in the rHuEPO group and 15 patients (53.6%) in control group, received transfusions because their hemoglobin level were below 7 g/dl. There was a significant decrease in requiring transfusions in rHuEPO group in compared to control group at the end of study (P=0.004) (<xref ref-type="table" rid="T2">Table II</xref>). Among the participants, 46 patients (80.7%) were used G-CSF to treatment </p><p>of concurrently neutropenia during the study in both groups. 24 patients (82.4%) in rHuEPO group and 22 patients (78.5%) in control group were used G-CSF during the study. In this study, there was no significant difference in Hb level between the patients received G-CSF and those that did not use (P =0.64). The mean initial Hb levels in both groups, with or without receiving G-CSF, were 8.91&#x000b1;0.07 g/dl and 8.99&#x000b1;0.16 g/dl, respectively (p=0.66). The mean final Hb levels in the patients who received G-CSF and those that did not use it were 8.93&#x000b1;0.25 g/dl and 8.61&#x000b1;0.61 g/dl, respectively (0.64) (<xref ref-type="table" rid="T4">Table IV</xref>). Among 29 patients exposed to EPREX treatment, 35 adverse events were reported: 12 cases in weeks 1-4, 12 cases in weeks 5-8, and 11 casesin weeks 8-12. The most frequent AE was vomiting (40%), followed by fever (22.8%), bone pain (17.1%), flu-like syndrome (11.4%), flashing (5.7%), and hypertension (2.85%), (<xref ref-type="table" rid="T5">Table V</xref>). It was found no other side effects for rHuEPO treatment during the study. Considering total AE reported, only one patient was found with uncontrolled hypertension at week 4 and stopped the treatment. All other AE reported were transient, which did not reoccur after transient discontinuation of the medication.</p><table-wrap id="T1" position="float"><label>Table I</label><caption><p>Type of malignancies in participating patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold> Type of Malignancy</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Total</bold>
<break/>
<bold>n(%)</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>rHuEPO Group</bold>
<break/>
<bold>n(%)</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Control Group</bold>
<break/>
<bold>n(%)</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>p-value</bold>
</th></tr></thead><tbody><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Non Hodgkin lymphoma</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">7(12.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3 (5.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">4 (7)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hodgkin lymphoma</bold>
</td><td align="center" rowspan="1" colspan="1">6 (10.5)</td><td align="center" rowspan="1" colspan="1">3 (5.25)</td><td align="center" rowspan="1" colspan="1">3 (5.25)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Epandimoma</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3 (5.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2 (3.5)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Meduloblastoma </bold>
</td><td align="center" rowspan="1" colspan="1">3 (5.25)</td><td align="center" rowspan="1" colspan="1">1 (1.75)</td><td align="center" rowspan="1" colspan="1">2 (3.5)</td><td align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Neuroblastoma</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">8 (14)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3 (5.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">5 (8.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Rhabdomyosarcoma </bold>
</td><td align="center" rowspan="1" colspan="1">5 (8.75)</td><td align="center" rowspan="1" colspan="1">3 (5.25)</td><td align="center" rowspan="1" colspan="1">2 (3.5)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Ewing Sarcoma </bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">5 (8.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3 (5.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2 (3.5)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Osteosarcoma </bold>
</td><td align="center" rowspan="1" colspan="1">3 (5.25)</td><td align="center" rowspan="1" colspan="1">1 (1.75)</td><td align="center" rowspan="1" colspan="1">2 (3.5)</td><td align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Synovial Sarcoma</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0 (0)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Fibrosarcoma</bold>
</td><td align="center" rowspan="1" colspan="1">1 (1.75)</td><td align="center" rowspan="1" colspan="1">1 (1.75)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Yolk Sac Tumor </bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3 (5.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2 (3.5)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Germinoma </bold>
</td><td align="center" rowspan="1" colspan="1">2 (3.5)</td><td align="center" rowspan="1" colspan="1">1 (1.75)</td><td align="center" rowspan="1" colspan="1">1 (1.75)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Hepatoblastoma </bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3 (5.25)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2 (3.5)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wilms Tumor </bold>
</td><td align="center" rowspan="1" colspan="1">6 (10.5)</td><td align="center" rowspan="1" colspan="1">4 (7)</td><td align="center" rowspan="1" colspan="1">2 (3.5)</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Nasopharyngeal Carcinoma</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1 (1.75)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0 (0)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">29 (50.8)</td><td align="center" rowspan="1" colspan="1">28 (49.2)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table II</label><caption><p>Demographic and Hematologic parameters in participating patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4F81BD;" align="center" colspan="3" rowspan="1">
<bold>Variable</bold>
</th><th style="background-color:#4F81BD;" align="center" colspan="2" rowspan="1">
<bold>rHEPO Group</bold>
<break/>
<bold>n=29</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Control Group</bold>
<break/>
<bold>n=28</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr></thead><tbody><tr><td style="background-color:#D3DFEE;" align="justify" rowspan="2" colspan="1">
<bold>Gender</bold>
</td><td style="background-color:#D3DFEE;" align="justify" colspan="3" rowspan="1">Female</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">12(41.4%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">15 (53.6%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.36<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" colspan="3" rowspan="1">Male</td><td align="center" rowspan="1" colspan="1">17(58.6%)</td><td align="center" rowspan="1" colspan="1">13 (46.4%)</td><td align="center" rowspan="1" colspan="1">0.36<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td style="background-color:#D3DFEE;" align="justify" rowspan="2" colspan="1">
<bold>Age </bold>
</td><td style="background-color:#D3DFEE;" align="justify" colspan="3" rowspan="1">Mean</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">6.43&#x000b1;0.38</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">6.11&#x000b1;0.83</td><td style="background-color:#D3DFEE;" align="center" rowspan="2" colspan="1">0.78<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="justify" colspan="3" rowspan="1">Range</td><td align="center" rowspan="1" colspan="1">0.9-14</td><td align="center" rowspan="1" colspan="1">1-14</td></tr><tr><td style="background-color:#D3DFEE;" align="justify" colspan="2" rowspan="2">
<bold>Mean Hemoglobin (g/dl)</bold>
</td><td style="background-color:#D3DFEE;" align="left" colspan="2" rowspan="1">Onset of study</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">8.85&#x000b1;1.01</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">9.00&#x000b1;0.09</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.25<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" colspan="2" rowspan="1">End of study</td><td align="center" rowspan="1" colspan="1">9.90&#x000b1;0.29</td><td align="center" rowspan="1" colspan="1">7.81&#x000b1;0.23</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td style="background-color:#D3DFEE;" align="justify" colspan="4" rowspan="1">
<bold>&#x02206; Hb (g/dl) ) end of study</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">+ 1.04&#x000b1;0.31</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">- 1.31&#x000b1;0.24</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="justify" colspan="4" rowspan="1">
<bold>Number of Transfusion (%)</bold>
</td><td align="center" rowspan="1" colspan="1">5 (17.2%)</td><td align="center" rowspan="1" colspan="1">15 (53.6%)</td><td align="center" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p> Chi-Square Test</p></fn><fn id="TFN2"><label>**</label><p>Independent Samples Test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table III</label><caption><p>Patients Characteristics used CDDP in rHuEPO group &#x00026; Control group</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4F81BD;" align="center" colspan="2" rowspan="1">
<bold>Variable</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>rHuEPO Group</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Control Group</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>p-value</bold>
</th></tr></thead><tbody><tr><td style="background-color:#D3DFEE;" align="justify" colspan="2" rowspan="1">
<bold>Number of patients (%)</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">11 (37.9%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">14 (50%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.36<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="justify" rowspan="2" colspan="1">
<bold>Mean hemoglobin level (g/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">Onset of study</td><td align="center" rowspan="1" colspan="1">8.89&#x000b1;0.21</td><td align="center" rowspan="1" colspan="1">9.06&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">0.54<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td style="background-color:#D3DFEE;" align="justify" rowspan="1" colspan="1">End of study</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">9.67&#x000b1;0.49</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">7.71&#x000b1;0.36</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td align="justify" colspan="2" rowspan="1">
<bold>&#x02206; Hb (g/dl) at the end of study</bold>
</td><td align="center" rowspan="1" colspan="1">+ 0.78&#x000b1;0.59</td><td align="center" rowspan="1" colspan="1">- 1.35&#x000b1;0.33</td><td align="center" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td style="background-color:#D3DFEE;" align="justify" colspan="2" rowspan="1">
<bold>Number of patients who had Transfusion (%)</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2 (40%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">7 (46.6%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.21<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p>Chi-Square Test</p></fn><fn id="TFN4"><label>**</label><p>Mann-Whitney Test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table IV</label><caption><p>Patients Characteristics used G-CSF in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4F81BD;" align="center" colspan="2" rowspan="1">
<bold>Variable</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Patients used G-CSF</bold>
<break/>
<bold>n= 46</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Patients not used G-CSF</bold>
<break/>
<bold>n=11</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>p-value</bold>
</th></tr></thead><tbody><tr><td style="background-color:#D3DFEE;" align="justify" rowspan="2" colspan="1">
<bold>Mean hemoglobin level (g/dl)</bold>
</td><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">Onset of study</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">8.91&#x000b1;0.07</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">8.99&#x000b1;0.16</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.66<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="justify" rowspan="1" colspan="1">End of study</td><td align="center" rowspan="1" colspan="1">8.93&#x000b1;0.25</td><td align="center" rowspan="1" colspan="1">8.61&#x000b1;0.61</td><td align="center" rowspan="1" colspan="1">0.64<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td style="background-color:#D3DFEE;" align="justify" colspan="2" rowspan="1">
<bold>&#x02206; Hb (g/dl) at the end of study</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">+0.01&#x000b1;0.27</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">-0.6&#x000b1;0.65</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0.28<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="justify" colspan="2" rowspan="1">
<bold>Number of patients who had Transfusion (%)</bold>
</td><td align="center" rowspan="1" colspan="1">4 (80%)</td><td align="center" rowspan="1" colspan="1">11 (73.3%)</td><td align="center" rowspan="1" colspan="1">0.20<xref ref-type="table-fn" rid="TFN5">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>*</label><p>Chi-Square Test</p></fn><fn id="TFN6"><label>**</label><p>Mann-Whitney Test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table V</label><caption><p>Adverse events during rHuEPO treatment<xref ref-type="table-fn" rid="TFN7">*</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Adverse event</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Weeks 1-4</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Weeks 5-8</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Weeks 9-12</bold>
</th><th style="background-color:#4F81BD;" align="center" rowspan="1" colspan="1">
<bold>Total (%)</bold>
</th></tr></thead><tbody><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Vomiting</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">5(14.2%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3(8.6%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">6(17.2)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">14(40)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Fever</bold>
</td><td align="center" rowspan="1" colspan="1">2(5.7%)</td><td align="center" rowspan="1" colspan="1">4(11.4%)</td><td align="center" rowspan="1" colspan="1">2(5.7%)</td><td align="center" rowspan="1" colspan="1">8(22.8)</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Bone pain</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1(2.9%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">3(8.6%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2(5.7%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">6(17.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Flu-like syndrome</bold>
</td><td align="center" rowspan="1" colspan="1">1(2.85%)</td><td align="center" rowspan="1" colspan="1">2(5.7%)</td><td align="center" rowspan="1" colspan="1">1(2.85%)</td><td align="center" rowspan="1" colspan="1">4(11.4)</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Flashing</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1(2.85%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">0(0%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">1(2.85%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">2(5.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hypertension</bold>
</td><td align="center" rowspan="1" colspan="1">1(2.9%)</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">1(2.9)</td></tr><tr><td style="background-color:#D3DFEE;" align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">11(31.4%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">12(34.3%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">12(34.3%)</td><td style="background-color:#D3DFEE;" align="center" rowspan="1" colspan="1">35(100)</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>*</label><p> Analysis of 29 patients were included in rHuEPO group</p></fn></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Comparison of hemoglobin ascending trend in rHuEPO and control groups who completing study course.</p></caption><graphic xlink:href="ijpho-4-151-g001"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Anemia is a common issue in patients receiving chemotherapy, with incidence rates ranging from 51% to 74% for solid tumors and Hodgkin disease, and as high as 97% for leukemia in pediatric populations [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. Traditional therapy of chemotherapy-induced anemia was RBC transfusion, despite their short-lived effects and inherent risks [<xref rid="B38" ref-type="bibr">38</xref>-<xref rid="B45" ref-type="bibr">45</xref>]. rHuEPO treatment can improve quality of life in adult patients with chemotherapy, regardless of the disease type and the response to chemotherapy [<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>]. The efficacy of rHuEPO in children receiving chemotherapy is still controversial. Benefits of erythropoietin in adult treatment of chemotherapy-induced anemia were first demonstrated by Miller. Significant difference was observed in the effect of rHuEPO at dosage of 100-200 units/kg/day on increasing hemoglobin level in patients undergoing chemotherapy with and without CDDP in this study[<xref rid="B8" ref-type="bibr">8</xref>]. </p><p>In a study by Porter, on 24 patients with a variety of malignant solid tumors, the use of rHuEPO of 150 units/ kg/ dose, 3 days per week, was associated with reducing the need for blood transfusion and increasing the level of hemoglobin in patients [<xref rid="B10" ref-type="bibr">10</xref>]. In Ragni's study on 22 patients with a variety of solid tumors, the use of rHuEPO at dosage of 150 units/ kg/ dose, 3 days per week, had positive effects on increasing patients&#x02019; hemoglobin level [<xref rid="B12" ref-type="bibr">12</xref>]. In both above studies, the use of recombinant human erythropoietin was also associated with reducing platelet transfusion [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. In a study by Nenadov, rHuEPO at dosage of 100 units/ kg/ dose, for two weeks, left no positive effect on the treatment of chemotherapy-inducedanemia in children [<xref rid="B30" ref-type="bibr">30</xref>]. In Kim's study, the use of rHuEPO at dosage of 150 units/ kg/ dose, 3 days per week, for 12 weeks was associated with reducing the need for blood transfusion in the receiving group [<xref rid="B27" ref-type="bibr">27</xref>]. In a study by B&#x000fc;y&#x000fc;kpamuk&#x000e7;u, on 34 patients with a variety of malignancies including solid tumors and lymphoma, the use of recombinant human erythropoietin at dosage of 150 units/ kg/ dose, 3 days per week, for 8 weeks was associated with reducing the need for blood transfusion and increasing hemoglobin in the receiving group [<xref rid="B28" ref-type="bibr">28</xref>].</p><p>In the present study, the use of rHuEPO at dosage of 150 units/ kg/ dose, 3 days per week, for 12 weeks in children with chemotherapy-induced anemia produced favorable outcomes such as reducing significantly (5 cases (17.2%) of blood transfusion in rHuEPO recieving group and 15 cases (53.6%) in control group) the need for blood transfusion over 12 weeks of treatment. In a few recent studies, increasing dose of rHuEPO and reducing drug injection interval produced a significant response for treating chemotherapy-induced anemia in children [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B35" ref-type="bibr">35</xref>-<xref rid="B37" ref-type="bibr">37</xref>]. In Razak's study, using rHuEPO at dosage of 600-900 units/ kg/ dose, once a week, on 22 patients with a variety of non-myeloid malignancies was associated with reducing the need for blood transfusion and increasing hemoglobin level [<xref rid="B36" ref-type="bibr">36</xref>]. In a study by Abdelrazik and Fouda , applying rHuEPO at dosage of 450 units/ kg/ dose, once a week on 60 patients with acute lymphoblastic leukemia could increase hemoglobin in anemic children and reduce the need for blood transfusion [<xref rid="B37" ref-type="bibr">37</xref>]. There are a few studies on positive effects of human erythropoietin in the treatment of cisplatin-induced anemia compared to regimens without cisplatin [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. In a study by Corazza, cisplatin nephrotoxicity played no significant role in decreasing erythropoietin production, while it could reduce bone marrow response to erythropoietin due to cispaltin-induced anemia. </p><p>In the present study, no significant difference was observed in increased level of hemoglobin at dosage of 150 units/ kg/ dose, 3 days per week, for 12 weeks in patients with regimens with and without cispaltin. In this study, rHuEPO significantly increased hemoglobin level after the 5<sup>th</sup> and 6<sup>th</sup> weeks, and its ascending trend continued to the end of the study. In the present study, the minimum acceptable hemoglobin level was 7 g/dl. This level varied from 6 to 9 g/dl in similar studies [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B43" ref-type="bibr">43</xref>-<xref rid="B45" ref-type="bibr">45</xref>]. In this study, there was one case of hypertension in rHuEPO receiving group and all of other reported AE were transient, and did not recur after temporary discontinuation of treatment. At the end of the study, we concluded that rHuEPO at dosage of 150 units/ kg/ dose; 3 days per week can be an effective and healthy treatment for chemotherapy-induced anemia in children. </p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Increasing dosage of rHuEPO may be necessary in patients undergoing chemotherapy with cisplatin.</p><p>However, in the present study, similar increase in the level of hemoglobin was observed in both groups. Concurrent use of G-CSF in neutropenic patients had no effect on increasing hemoglobin level by the end of the treatment with rHuEPO.</p></sec></body><back><ack><title>Acknowledgment</title><p>We wish to express a sincere thank you to all patients who so graciously agreed to participate in this study.</p></ack><sec><title>Conflict of interest</title><p>The authors declare no con&#x0fb02;ict of interest.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borsi</surname><given-names>JD</given-names></name><name><surname>Ferencz</surname><given-names>T</given-names></name><name><surname>Csaki</surname><given-names>C</given-names></name><etal/></person-group><article-title>Transfusion requirements of children with cancer and the use of recombinant erythropoietin for the prevention and treatment of cytostatics induced anemia in children [abstract]</article-title><source> Can J Infect Dis</source><year>1995</year><volume>6</volume><issue>suppl C</issue><lpage>235C</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockenberry</surname><given-names>MJ</given-names></name><name><surname>Hinds</surname><given-names>PS</given-names></name><name><surname>Barrera</surname><given-names>P</given-names></name><name><surname>Billups</surname><given-names>C</given-names></name><name><surname>Rodriguez-Galindo</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Incidence of anemia in children with solid tumors or Hodgkin disease</article-title><source> J Pediatr Hematol Oncol</source><year>2002</year><volume>24</volume><issue>1</issue><fpage>35</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11902737</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michon</surname><given-names>J</given-names></name></person-group><article-title>Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey</article-title><source> Med Pediatr Oncol</source><year>2002</year><volume>39</volume><issue>4</issue><fpage>448</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">12203661</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groopman</surname><given-names>JE</given-names></name><name><surname>Itri</surname><given-names>LM</given-names></name></person-group><article-title>Chemotherapy-induced anemia in adults: incidence and treatment</article-title><source> J Natl Cancer Inst</source><year>1999</year><volume>91</volume><issue>19</issue><fpage>1616</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">10511589</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of anemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin</article-title><source> Med Oncol</source><year>2000</year><volume>17</volume><issue>suppl 1</issue><fpage>S11</fpage><lpage>S16</lpage><pub-id pub-id-type="pmid">11188780</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Fedeli</surname><given-names>A</given-names></name><name><surname>Fedeli</surname><given-names>SL</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name></person-group><article-title>Cisplatin associated anemia treated with subcutaneous erythropoietin A pilot study</article-title><source>Br J Cancer</source><year>1993</year><volume>67</volume><issue>1</issue><fpage>156</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">8427776</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>DH</given-names></name></person-group><article-title>Clinical application of recombinant erythropoietin in anemic cancer patients</article-title><source> Hematol Oncol Clin North Am</source><year>1994</year><volume>8</volume><fpage>961</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">7852218</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CB</given-names></name><name><surname>Platanias</surname><given-names>LC</given-names></name><name><surname>Mills</surname><given-names>SR</given-names></name><name><surname>Zahurak</surname><given-names>ML</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name><name><surname>Ettinger</surname><given-names>DS</given-names></name><etal/></person-group><article-title>phase I-II trial of erythropoietin in the treatment of cisplatin associated anemia</article-title><source> J Natl Cancer Inst</source><year>1992</year><volume>84</volume><issue>2</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">1735886</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennetts</surname><given-names>G</given-names></name><name><surname>Bertolone</surname><given-names>S</given-names></name><name><surname>BrayG</surname><given-names/></name></person-group><article-title>Erythropoietin reduces volume of red cell transfusions in some subsets of children with acute lymphocytic leukaemia</article-title><source> Blood</source><year>1995</year><volume>10</volume><fpage>853</fpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>JC</given-names></name><name><surname>Leahey</surname><given-names>A</given-names></name><name><surname>Polise</surname><given-names>K</given-names></name><name><surname>Bunin</surname><given-names>G</given-names></name><name><surname>Manno</surname><given-names>CS</given-names></name></person-group><article-title>Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial</article-title><source> J Pediatr</source><year>1996</year><volume>129</volume><issue>5</issue><fpage>656</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8917229</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cs&#x000e1;ki</surname><given-names>C</given-names></name><name><surname>Ferencz</surname><given-names>T</given-names></name><name><surname>Schuler</surname><given-names>D</given-names></name><name><surname>Borsi</surname><given-names>JD</given-names></name></person-group><article-title>Recombinant human erythropoietin in the prevention of chemotherapy-induced anemia in children with malignant solid tumours</article-title><source> European Journal of Cancer</source><year>1998</year><volume>34</volume><issue>3</issue><fpage>364</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">9640223</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragni</surname><given-names>G</given-names></name><name><surname>Clerico</surname><given-names>A</given-names></name><name><surname>Sordi</surname><given-names>A</given-names></name></person-group><article-title>Recombinant human erythropoietin (rHuEPO) in children with cancer A randomized study</article-title><source>Med Pediatr Oncol</source><year>1998</year><volume>31</volume><fpage>274</fpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leo&#x000b4;n</surname><given-names>P</given-names></name><name><surname>Jime&#x000b4;nez</surname><given-names>M</given-names></name><name><surname>Barona</surname><given-names>P</given-names></name><name><surname>Sierrasesu&#x000b4;maga</surname><given-names>L</given-names></name></person-group><article-title>Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors</article-title><source> Med Pediatr Oncol</source><year>1998</year><volume>30</volume><issue>2</issue><fpage>110</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">9403020</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelieveld</surname><given-names>P</given-names></name><name><surname>Van</surname><given-names>der Vijgh WJ</given-names></name><name><surname>Veldhuizen</surname><given-names>RW</given-names></name><name><surname>Van</surname><given-names>Velzen D</given-names></name><name><surname>Van</surname><given-names>Putten LM</given-names></name><name><surname>Atassi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives</article-title><source> Eur J Clin Oncol.</source><year> 1984</year><volume>20</volume><issue>8</issue><fpage>1087</fpage><lpage>104</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhotmann</surname><given-names>SA</given-names></name><name><surname>Paul</surname><given-names>P</given-names></name><name><surname>Weick</surname><given-names>JK</given-names></name><name><surname>McIntyre</surname><given-names>WR</given-names></name><name><surname>Fantelli</surname><given-names>F</given-names></name></person-group><article-title>Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells</article-title><source> Int J Cell Cloning</source><year>1985</year><volume>3</volume><issue>6</issue><fpage>415</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">4067362</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasi</surname><given-names>R1</given-names></name><name><surname>Abriani</surname><given-names>L</given-names></name><name><surname>Beccaglia</surname><given-names>P</given-names></name><name><surname>Terzoli</surname><given-names>E</given-names></name><name><surname>Amadori</surname><given-names>S</given-names></name></person-group><article-title>Cancer-related fatigue: evolving concepts in evaluation and treatment</article-title><source> Cancer</source><year>2003</year><volume>98</volume><issue>9</issue><fpage>1786</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">14584059</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobrero</surname><given-names>A</given-names></name><name><surname>Puglisi</surname><given-names>F</given-names></name><name><surname>Guglielmi</surname><given-names>A</given-names></name><name><surname>Belvedere</surname><given-names>O</given-names></name><name><surname>Aprile</surname><given-names>G</given-names></name><name><surname>Ramello</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fatigue: a main component of anemia symptomatology</article-title><source> Semin Oncol</source><year>2001</year><volume>28</volume><issue>2, suppl 8</issue><fpage>15</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11395847</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>MJ</given-names></name><name><surname>Huether</surname><given-names>SE</given-names></name><name><surname>Witte</surname><given-names>MK</given-names></name></person-group><article-title>Effect of red blood cell transfusion on oxygen consumption in the anemic pediatric patient</article-title><source> Pediatr Crit Care Med</source><year>2003</year><volume>4</volume><issue>4</issue><fpage>459</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">14525643</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mock</surname><given-names>V</given-names></name><name><surname>Olsen</surname><given-names>M</given-names></name></person-group><article-title>Current management of fatigue and anemia in patients with cancer</article-title><source> Semin Oncol Nurs</source><year>2003</year><volume>19</volume><issue>4, suppl 2</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">14702919</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hokenberry-Eaton</surname><given-names>M</given-names></name><name><surname>Hinds</surname><given-names>PS</given-names></name></person-group><article-title>Fatigue in children and adolescent with cancer: evolution of a program of study</article-title><source> Semin Oncol Nurs</source><year>2000</year><volume>16</volume><issue>4</issue><fpage>261</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11109271</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>K</given-names></name><name><surname>Wade</surname><given-names>S</given-names></name><name><surname>Balducci</surname><given-names>L</given-names></name></person-group><article-title>prevalence and outcomes of anemia in cancer: a systematic review of the literature</article-title><source> Am J Med</source><year>2004</year><volume>116</volume><issue>suppl 7A</issue><fpage>11S</fpage><lpage>26S</lpage><pub-id pub-id-type="pmid">15050883</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van-Steenkiste</surname><given-names>J</given-names></name></person-group><article-title>pharmacotherapy of chemotherapy-induced anemia</article-title><source> Expert Opin Pharmacother</source><year>2003</year><volume>4</volume><issue>12</issue><fpage>2221</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">14640921</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Fedeli</surname><given-names>A</given-names></name><name><surname>Del</surname><given-names>Ferro E</given-names></name><name><surname>Fedeli</surname><given-names>SL</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name></person-group><article-title>Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo</article-title><source> J Clin Oncol</source><year>1994</year><volume>12</volume><issue>5</issue><fpage>1058</fpage><lpage>062</lpage><pub-id pub-id-type="pmid">8164030</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrilove</surname><given-names>JL1</given-names></name><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Livingston</surname><given-names>RB</given-names></name><name><surname>Sarokhan</surname><given-names>B</given-names></name><name><surname>Winer</surname><given-names>E</given-names></name><name><surname>Einhorn</surname><given-names>LH</given-names></name></person-group><article-title>Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing</article-title><source> J Clin Oncol</source><year>2001</year><volume>19</volume><issue>11</issue><fpage>2875</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">11387360</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaspy</surname><given-names>J</given-names></name><name><surname>Vadhan-Raj</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Bosserman</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Lloyd</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Randomized comparison of every 2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy- induced anemia: The 20030125 Study Group Trial</article-title><source> J Clin Oncol</source><year>2006</year><volume>24</volume><issue>15</issue><fpage>2290 </fpage><lpage>297</lpage><pub-id pub-id-type="pmid">16710026</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corazza</surname><given-names>F1</given-names></name><name><surname>Beguin</surname><given-names>Y</given-names></name><name><surname>Bergmann</surname><given-names>P</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>M</given-names></name><name><surname>Ferster</surname><given-names>A</given-names></name><name><surname>Devalck</surname><given-names>C</given-names></name><etal/></person-group><article-title>Anemia in children with cancer Is Associated with decreased erythropoietic activity and Not with inadequate erythropoietin production</article-title><source> Blood</source><year>1998</year><volume>92</volume><issue>5</issue><fpage>1793</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">9716610</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Recombinant human erythropoietin for the prevention and treatment of chemotherapy induced anemia in childhood cancer</article-title><source> J Korean Med Sci</source><year>2002</year><volume>17</volume><fpage>337</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">12068136</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varan</surname><given-names>A1</given-names></name><name><surname>B&#x000fc;y&#x000fc;kpamuk&#x000e7;u</surname><given-names>M</given-names></name><name><surname>Kutluk</surname><given-names>T</given-names></name><name><surname>Aky&#x000fc;z</surname><given-names>C</given-names></name></person-group><article-title> Recombinant human erythropoietin treatment for chemotherapy-related anemia in children</article-title><source>Pediartics</source><year>1999</year><volume>103</volume><issue>2</issue><fpage>e16</fpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henze</surname><given-names>G</given-names></name><name><surname>Michon</surname><given-names>J</given-names></name><name><surname>Morland</surname><given-names>B</given-names></name><etal/></person-group><article-title>Phase III randomized study: Efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy</article-title><source> Proc Am Soc Clin Oncol</source><year>2002</year><volume>21</volume><fpage>387a</fpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nenadov</surname><given-names>Beck M</given-names></name><name><surname>Beck</surname><given-names>D</given-names></name></person-group><article-title>Recombinant erythropoietin in acute chemotherapy- induced anemia of children with cancer</article-title><source> Med Pediatr Oncol</source><year>1995</year><volume>25</volume><issue>1</issue><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7752997</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>JD1</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name><name><surname>Hagerty</surname><given-names>KL</given-names></name><name><surname>Seidenfeld</surname><given-names>J</given-names></name><name><surname>Bohlius</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Use of Epoetin and Darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update</article-title><source> J Clin Oncol</source><year>2008</year><volume>26</volume><issue>1</issue><fpage>132</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">17954713</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>World</surname><given-names>Medical Association Declaration of Helsinki</given-names></name></person-group><article-title>Ethical principles for Medical Research involving Human Subjects [Internet]</article-title><year>1964</year><publisher-loc>Helsinki</publisher-loc><comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.ethics.hbi.ir">http://www.ethics.hbi.ir</ext-link></comment></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlewood</surname><given-names>TJ</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Nortier</surname><given-names>JW</given-names></name><name><surname>Vercammen</surname><given-names>E</given-names></name><name><surname>Rapoport</surname><given-names>B; Epoetin Alfa Study Group</given-names></name></person-group><article-title>Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial</article-title><source> J Clin Oncol</source><year>2001</year><volume>19</volume><issue>11</issue><fpage>2865</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">11387359</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Kris</surname><given-names>M</given-names></name><name><surname>Wade</surname><given-names>J</given-names></name><name><surname>Degos</surname><given-names>L</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name></person-group><article-title> Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study&#x02014;Procrit Study Group</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><issue>10</issue><fpage>3412</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">9779721</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durmaz</surname><given-names>O</given-names></name><name><surname>Demirkaya</surname><given-names>M</given-names></name><name><surname>Sevinir</surname><given-names>B</given-names></name></person-group><article-title>Recombinant human erythropoietin &#x003b2;: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients</article-title><source> Pediatr Hematol Oncol</source><year>2011</year><volume>28</volume><issue>6</issue><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">21707225</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzouk</surname><given-names>BI</given-names></name><name><surname>Hord</surname><given-names>JD</given-names></name><name><surname>Hockenberry</surname><given-names>M</given-names></name><name><surname>Hinds</surname><given-names>PS</given-names></name><name><surname>Feusner</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><etal/></person-group><article-title>Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy</article-title><source> J Clin Oncol</source><year>2006</year><volume>24</volume><issue>22</issue><fpage>3583</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">16877725</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelrazik</surname><given-names>N</given-names></name><name><surname>Fouda</surname><given-names>M</given-names></name></person-group><article-title>Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study</article-title><source> Hematology</source><year>2007</year><volume>12</volume><issue>6</issue><fpage>533</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17852440</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosanquet</surname><given-names>N</given-names></name><name><surname>Tolley</surname><given-names>K</given-names></name></person-group><article-title>Treatment of anemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan</article-title><source> Curr Med Res Opin</source><year>2003</year><volume>19</volume><issue>7</issue><fpage>643</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">14606988</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>GR</given-names></name></person-group><article-title>Blood transfusions in children with cancer and hematologic disorders: why, when, and how? (commentary)</article-title><source> Pediatr Blood Cancer</source><year>2005</year><volume>44</volume><fpage>114</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15578665</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>EC</given-names></name><name><surname>Perez-Albuerne</surname><given-names>E</given-names></name><name><surname>Moscow</surname><given-names>JA</given-names></name><name><surname>Luban</surname><given-names>NL</given-names></name></person-group><article-title>transfusion management strategies: a survey of practicing pediatric hematology/oncology specialists</article-title><source> Pediatr Blood Cancer</source><year>2005</year><volume>44</volume><issue>2</issue><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">15452914</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossetto</surname><given-names>CL</given-names></name><name><surname>McMahon</surname><given-names>JE</given-names></name></person-group><article-title>Current and future trends in transfusion therapy</article-title><source> J Pediatr Oncol Nurs</source><year>2000</year><volume>17</volume><issue>3</issue><fpage>160</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">10944864</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>J</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>PC</given-names></name><name><surname>Hutchison</surname><given-names>JS</given-names></name><name><surname>Hume</surname><given-names>HA</given-names></name><name><surname>Tucci</surname><given-names>M</given-names></name><name><surname>Ducruet</surname><given-names>T</given-names></name><etal/></person-group><article-title>Transfusion strategies for patients in pediatric intensive care units</article-title><source> N Engl J Med</source><year>2007</year><volume>365</volume><issue>16</issue><fpage>1609</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">17442904</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marec-Berard</surname><given-names>P</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name><name><surname>Schell</surname><given-names>M</given-names></name><name><surname>Buclon</surname><given-names>M</given-names></name><name><surname>Demaret</surname><given-names>C</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name></person-group><article-title>Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients</article-title><source> J Clin Oncol</source><year>2003</year><volume>21</volume><issue>22</issue><fpage>4235</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">14615453</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>A</given-names></name><name><surname>Riccardi</surname><given-names>R</given-names></name></person-group><article-title>Intrerventions for anemia in pediatric cancer patients</article-title><source> Med Pediatr Oncol</source><year>2002</year><volume>39</volume><issue>4</issue><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">12203662</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>D</given-names></name><name><surname>Rogers</surname><given-names>ZR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Altman</surname><given-names>A</given-names></name></person-group><article-title>Blood component therapy</article-title><source>Supportive care of children with cancer: current therapy and guidelines from the children's Oncology Group</source><year>2004</year><publisher-loc>Baltimore and London</publisher-loc><publisher-name>The Johns Hopkins University Press</publisher-name><fpage>39</fpage><lpage>57</lpage></element-citation></ref></ref-list></back></article>